Choosing Between Pramlintide and Cagrilintide: A 2026 Decision Guide

Pramlintide at a glance:

• Drug class: Amylin analog
• Manufacturer: AstraZeneca (originally Amylin Pharmaceuticals)
• FDA approved: 2005
• Route: subcutaneous injection
• Typical frequency: before each major meal
• Half-life: approximately 48 minutes
• Cash price (US): $300-$600/month
• Receptor target: amylin receptors

Head-to-head comparisons in this space are useful but easy to overweight. The truth is that most differences shake out to a couple of percentage points of efficacy and a different side-effect distribution. Here's how the two compare.

Mechanism

Pramlintide: Pramlintide is a synthetic amylin analog used with mealtime insulin to suppress glucagon, slow gastric emptying, and reduce postprandial glucose spikes.

Cagrilintide: Cagrilintide is an engineered amylin analog with extended half-life suitable for weekly dosing. Amylin co-released with insulin from beta cells suppresses glucagon, slows gastric emptying, and increases satiety.

For people new to this comparison, the practical takeaway is that the underlying mechanisms are different enough that response can vary.

Dosing & Administration

Effectiveness

Pramlintide: Modest A1c reductions (0.3-0.6%) and weight loss (1-2 kg) when added to insulin.

Cagrilintide: Monotherapy phase 2 showed weight loss of 6-10%; combination with semaglutide pushed total weight loss above 17%.

In head-to-head comparisons (where they exist), the higher-dose newer agents tend to outperform older ones — sometimes meaningfully. Reference trials: Multiple phase 3 trials in T1D and T2D demonstrated A1c and weight benefits for Pramlintide; Lau et al for Cagrilintide.

Side Effects

The two compounds have overlapping side-effect profiles. Common to both:

• nausea
• anorexia
• vomiting
• headache
• decreased appetite
• diarrhea

Important risks worth knowing for both:

• severe hypoglycemia when combined with mealtime insulin (boxed warning)
• limited long-term data

Cost

Pramlintide: $300-$600/month. Cagrilintide: pricing varies.

Insurance coverage and manufacturer programs change the relative cost picture significantly. See our individual cost guides for Pramlintide cost and Cagrilintide cost for the latest numbers.

Which Is Right for You?

The practical decision usually comes down to four factors:

1. What's covered by your insurance? Often the deciding factor
2. What does your prescriber have experience with? Familiarity reduces dosing errors
3. How comfortable are you with injections (or oral dosing if applicable)?
4. What's your tolerance for side effects?

If you and your clinician end up split between Pramlintide and Cagrilintide, either is a defensible choice in most cases.

Switching Between Them

Switching from Pramlintide to Cagrilintide (or the reverse) is usually straightforward but should be done with clinician guidance — particularly to align dose escalation and avoid GI side effects from re-titration.

Bottom Line

Head-to-head comparisons are useful but rarely decisive. The bigger swing factors are usually outside the comparison itself.

Frequently Asked Questions

Related Reading

• Is Pramlintide Right for You? An Evidence-Based Breakdown
• Is Pramlintide Safe? An Honest Look at the Side-Effect Profile
• Pramlintide Results: Realistic Expectations vs. Trial Headlines
• How Much Does Pramlintide Really Cost? The Honest Breakdown
• Is Retatrutide Right for You? An Evidence-Based Breakdown
• What Nobody Tells You About Retatrutide Side Effects

Sources

• Le Roux CW et al. Survodutide for the Treatment of Obesity — Phase 2. Lancet 2024;403:888.
• Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). NEJM 2022;387:205.
• Jastreboff AM et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — Phase 2 Trial. NEJM 2023;389:514.

This page is informational only and is not a personalized recommendation. The right choice depends on your individual situation.